Review of ibogaine's heart risks: QT prolongation and dangerous arrhythmias

The question

How serious is the heart risk from ibogaine, a psychoactive plant alkaloid being studied for addiction, and what could make its use safer?

What they did

The authors reviewed published evidence on ibogaine and its metabolite noribogaine. They drew on observational studies, open-label studies, a limited number of randomized placebo-controlled trials, and case reports of harm. They also reviewed work on how the body breaks ibogaine down and on newer chemical relatives of the drug.

What they found

The reviewed evidence suggests ibogaine and noribogaine can reduce craving and withdrawal in people dependent on opioids and cocaine, acting through several pharmacological pathways. But the review flags a rare and clinically important heart risk: prolongation of the QTc interval (a delay in the heart’s electrical recycling) and potentially fatal ventricular arrhythmias, including Torsades de Pointes. Case reports show these events happened at therapeutic doses and in people with no known pre-existing heart disease. The authors note wide person-to-person variation in CYP2D6, the liver enzyme that processes ibogaine, which may make some people more vulnerable. Efforts to improve safety include altered dosing strategies, cardiac monitoring, and ibogaine analogues that kept anti-addictive effects without heart toxicity in animal and laboratory models.

The fine print

This is a narrative review, not a pooled statistical analysis, and the abstract reports no numbers, no sample sizes and no rates of harm. Much of the safety evidence comes from case reports, which cannot tell us how often these events occur. The safer analogues have only been tested in preclinical models, not in people. This summary is based on the abstract alone.

What it means

Ibogaine shows anti-addictive potential in early research, but the same evidence base documents rare heart rhythm complications that have occurred at treatment doses and in people without known heart problems, which is why the authors call for strict medical supervision and cardiac monitoring in any future use.

Evidence grade: Low. This is a narrative review that summarizes case reports, observational data and a small number of trials rather than reporting new controlled data.

This summary is based on the study’s published abstract.